FBLG today
$0.93-$0.04 (-4.21%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourExpanding
1 hourSymmetric Triangle
15 minStrong Bearish
5 minConsolidating
Daily trend turns up above $2.20
Key levels
Resistance$1.24
Resistance$1.04
Support$0.90
Support$0.80
Latest news & SEC filings
LegalFibroBiologics granted European patent covering tumor-fighting agent delivery via fibroblasts
NewsFibroBiologics wins European patent for engineered fibroblast tumor-homing and therapy delivery
ProductFibroBiologics reports preclinical data on FSdC spheroids in rabbit disc model
All FBLG news →About FibroBiologics
FibroBiologics is a clinical-stage biotechnology company developing therapies based on fibroblast cells to treat chronic diseases. Its main product candidates include CYWC628 for wound healing, CYMS101 for multiple sclerosis, CybroCell for degenerative disc disease, and CYPS317 for psoriasis, with research also in certain cancers and longevity applications. The company operates in the United States and Australia, targeting patients with significant unmet medical needs.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
FibroBiologics, Inc. (FBLG)
What Is the Price Target for FBLG?
SEPT Low Target
$6.00
SEPT Mid Target
$6.00
SEPT High Target
$6.00
Analyst Consensus
$6.00
Is FBLG a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for FBLG.
Start Free Trial →Is FBLG Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$6.00
7
Moat Score
NONE
3/9
Piotroski Score
-5.8
Altman Z-Score
What Is Smart Money Doing with FBLG?
Insider Signal
BUYING
5 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →FBLG Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-23.53%
FCF Growth YoY
-37.8%
Revenue Trend
UNKNOWN
Dark Pool Trades for FBLG
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for FBLG, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:54:55 | $0.95 | 3,200 | $$3K | SELL |
| 19:46:58 | $0.94 | 2,580 | $$2K | SELL |
| 19:26:09 | $0.96 | 1,406 | $$1K | SELL |
| 19:15:04 | $0.96 | 1,602 | $$2K | SELL |
| 19:14:18 | $0.97 | 2,000 | $$2K | BUY |
5 dark pool trades shown · $$10K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for FibroBiologics, Inc. (FBLG) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →FBLG — frequently asked questions
What is FBLG stock price today?
FibroBiologics, Inc. (FBLG) is at $0.93, down 4.21% (-$0.04) at the Nov 13, 2026 close.
Why is FBLG stock moving today?
Latest FBLG news — Nov 7, 2026: FibroBiologics granted European patent covering tumor-fighting agent delivery via fibroblasts · Nov 5, 2026: FibroBiologics wins European patent for engineered fibroblast tumor-homing and therapy delivery
What is the FBLG price target?
The average analyst price target for FBLG is $6.00, ranging from $6 to $6, based on 1 analysts. Latest: HC Wainwright & Co. maintains on Aug 4, 2026.
What do analysts rate FBLG?
Analyst ratings for FBLG: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did FBLG beat earnings?
FBLG last reported on Jul 31, 2026: EPS -$0.66 vs -$0.72 expected — a beat of 8.3%.
What is FBLG's P/E ratio?
FBLG trades at a P/E of 0.4 vs a Healthcare average of 17.7.
Does FBLG pay a dividend?
FBLG does not currently pay a dividend.
What are FBLG support and resistance levels?
Support: $0.90, $0.80, $0.62. Resistance: $1.04, $1.24, $1.48.
What are insiders doing with FBLG?
Insider activity: BUYING, 5 buys and 0 sells in the last 90 days.
What is the latest news on FBLG?
Nov 7, 2026: FibroBiologics granted European patent covering tumor-fighting agent delivery via fibroblasts · Nov 5, 2026: FibroBiologics wins European patent for engineered fibroblast tumor-homing and therapy delivery · Oct 19, 2026: FibroBiologics reports preclinical data on FSdC spheroids in rabbit disc model